Trademark Overview
On Friday, May 17, 2024, a trademark application was filed for ENIGMA THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the ENIGMA THERAPEUTICS trademark a serial number of 98556226. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Friday, May 17, 2024. This trademark is owned by Enigma Therapeutics Ltd.. The ENIGMA THERAPEUTICS trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:
Pharmaceutical preparations and substances for the treatment of oncological diseases and disorders; pharmaceutical compositions for the treatment of oncological diseases and disorders; pharmaceutical preparations and substances for the treatment of autoimmune diseases and disorders; pharmaceutical compositions for the treatment of autoimmune diseases and disorders; biotechnological preparations for medical use; biotechnological preparations for the treatment of oncological diseases and disorders; biotechnological preparations for the treatment of autoimmune diseases and disorders; antibodies; antibodies for medical use; antigens; antigens for medical use; none of the aforementioned goods for dental purposes
Pharmaceutical research and development services; pharmaceutical drug development services; research and development of new pharmaceutical products for others; biomedical research services; medicine development services; pharmaceutical research; biochemical research and analysis; clinical trials; genome organization and functional analysis; genetic testing for scientific research; research and development services in the field of immunology, biotechnology, oncology, medicine, gene therapy, immunotherapy and therapeutics; research and development services in the field of antibodies and antigens; technological services related to manufacture of pharmaceuticals; laboratory services relating to the production of monoclonal antibodies; design of manufacturing methods for pharmaceuticals; advisory, information and consultancy services relating to the aforementioned services; none of the aforementioned services in relation to dentistry